BiotechTube
Home/Amarin Corporation/Michael W. Kalb
MW

Michael W. Kalb

Executive Vice President, Chief Legal Officer and Secretary

Amarin Corporation

Therapeutic Areas

Cardiovascular DiseaseMetabolic Disorders

Amarin Corporation Pipeline

DrugIndicationPhase
VASCEPA/VAZKEPA (Icosapent Ethyl)Cardiovascular Risk ReductionApproved
Icosapent EthylCV Risk Reduction (Post-Myocardial Infarction)Research

Leadership Team at Amarin Corporation

PH
Patrick Holt
President and Chief Executive Officer
AB
Aaron Berg
Executive Vice President and Chief Financial Officer
KM
Karim Mikhail
Executive Vice President and Chief Commercial Officer
SB
Steven B. Ketchum
Executive Vice President, President of R&D and Chief Scientific Officer
View full Amarin Corporation profile